Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Solaraze now being marketed for actinic keratosis in U.S.

Jan. 11, 2002

First patients treated in phase II trial of PhotoPoint drug MV-9411 in psoriasis

Jan. 11, 2002

Alexion's 5G1.1 completes phase I pilot study

Jan. 10, 2002

Life Medical Sciences given green light for trial of Repel-CV in neonatal patients

Jan. 9, 2002

Chugai researchers design vitamin D3 analogues with antipsoriatic activity

Jan. 4, 2002

Pharmacia granted rights to foam delivery technology for use with Rogaine

Jan. 4, 2002

GSK discontinues development of ADL-2-1294

Dec. 27, 2001

SkyePharma withdraws Solaraze termination notice

Dec. 27, 2001

Tetracyclic CXCR1/CXCR2 receptor antagonists in development at Pfizer

Dec. 18, 2001

U.S. clearance for Elidel Cream 1% for mild to moderate eczema

Dec. 18, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...